| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 26 | 2015 | 2756 | 1.570 |
Why?
|
| Neoplasm Metastasis | 19 | 2016 | 1038 | 1.200 |
Why?
|
| Neoplasms | 20 | 2015 | 2700 | 1.110 |
Why?
|
| Prostatic Neoplasms | 9 | 2007 | 1537 | 0.800 |
Why?
|
| Radiotherapy | 6 | 2014 | 325 | 0.760 |
Why?
|
| Antineoplastic Agents | 8 | 2015 | 2285 | 0.550 |
Why?
|
| Knowledge | 1 | 2014 | 25 | 0.540 |
Why?
|
| Education, Medical | 2 | 2014 | 219 | 0.520 |
Why?
|
| Neovascularization, Pathologic | 6 | 2004 | 337 | 0.510 |
Why?
|
| Physicians, Primary Care | 1 | 2014 | 99 | 0.480 |
Why?
|
| Models, Theoretical | 3 | 2005 | 479 | 0.480 |
Why?
|
| Randomized Controlled Trials as Topic | 5 | 2004 | 826 | 0.460 |
Why?
|
| Lymphatic Metastasis | 8 | 2003 | 466 | 0.450 |
Why?
|
| Physician-Patient Relations | 4 | 2007 | 581 | 0.430 |
Why?
|
| Humans | 71 | 2018 | 81308 | 0.430 |
Why?
|
| Radiation, Ionizing | 4 | 2010 | 120 | 0.410 |
Why?
|
| Radiation Oncology | 3 | 1997 | 121 | 0.390 |
Why?
|
| Human Experimentation | 1 | 2010 | 39 | 0.380 |
Why?
|
| Nucleoside-Diphosphate Kinase | 2 | 2000 | 11 | 0.380 |
Why?
|
| Ethics, Research | 1 | 2010 | 48 | 0.380 |
Why?
|
| Monomeric GTP-Binding Proteins | 2 | 2000 | 18 | 0.370 |
Why?
|
| Disease-Free Survival | 12 | 2011 | 1187 | 0.370 |
Why?
|
| Patient Advocacy | 3 | 2015 | 49 | 0.360 |
Why?
|
| MicroRNAs | 4 | 2015 | 511 | 0.350 |
Why?
|
| Chemotherapy, Adjuvant | 8 | 2005 | 446 | 0.340 |
Why?
|
| Genetic Therapy | 9 | 2008 | 334 | 0.340 |
Why?
|
| Physician's Role | 4 | 2005 | 178 | 0.330 |
Why?
|
| Models, Economic | 1 | 2007 | 61 | 0.320 |
Why?
|
| Hematopoiesis | 1 | 2008 | 158 | 0.320 |
Why?
|
| Liver Neoplasms | 3 | 2018 | 642 | 0.320 |
Why?
|
| Neoplasm Recurrence, Local | 5 | 2005 | 1226 | 0.310 |
Why?
|
| Neoplastic Stem Cells | 1 | 2008 | 131 | 0.310 |
Why?
|
| Decision Making | 3 | 2007 | 604 | 0.300 |
Why?
|
| Prostatectomy | 3 | 2007 | 442 | 0.300 |
Why?
|
| Androgen Antagonists | 2 | 2005 | 124 | 0.300 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2008 | 287 | 0.290 |
Why?
|
| Prognosis | 11 | 2005 | 3549 | 0.290 |
Why?
|
| Tumor Necrosis Factor-alpha | 7 | 2008 | 681 | 0.290 |
Why?
|
| Transcription Factors | 6 | 2004 | 1482 | 0.280 |
Why?
|
| Attitude of Health Personnel | 2 | 2005 | 628 | 0.280 |
Why?
|
| Colorectal Neoplasms | 3 | 2018 | 872 | 0.280 |
Why?
|
| Prostate-Specific Antigen | 2 | 1998 | 318 | 0.280 |
Why?
|
| Antineoplastic Agents, Hormonal | 2 | 2003 | 146 | 0.270 |
Why?
|
| Ethics, Medical | 3 | 2000 | 299 | 0.270 |
Why?
|
| Attitude to Health | 1 | 2005 | 219 | 0.260 |
Why?
|
| Nitriles | 1 | 2004 | 140 | 0.250 |
Why?
|
| Triazoles | 1 | 2004 | 96 | 0.250 |
Why?
|
| Biomedical Research | 3 | 2014 | 351 | 0.250 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2003 | 55 | 0.240 |
Why?
|
| History, 20th Century | 3 | 2010 | 306 | 0.240 |
Why?
|
| Managed Care Programs | 2 | 2000 | 42 | 0.230 |
Why?
|
| Brachytherapy | 1 | 2003 | 116 | 0.220 |
Why?
|
| Melanoma | 2 | 2013 | 431 | 0.220 |
Why?
|
| Proliferating Cell Nuclear Antigen | 2 | 2000 | 64 | 0.220 |
Why?
|
| Disease Progression | 8 | 2012 | 1436 | 0.220 |
Why?
|
| Lymph Node Excision | 1 | 2003 | 199 | 0.210 |
Why?
|
| Lymph Nodes | 4 | 2000 | 515 | 0.210 |
Why?
|
| Aged | 16 | 2018 | 17570 | 0.210 |
Why?
|
| Biomarkers, Tumor | 3 | 2003 | 1396 | 0.210 |
Why?
|
| Medical Oncology | 2 | 2014 | 334 | 0.200 |
Why?
|
| Female | 31 | 2018 | 42685 | 0.200 |
Why?
|
| Carcinoma | 1 | 2003 | 427 | 0.200 |
Why?
|
| Survival Analysis | 6 | 2013 | 1521 | 0.190 |
Why?
|
| African Americans | 2 | 1998 | 1079 | 0.190 |
Why?
|
| Combined Modality Therapy | 9 | 2005 | 1626 | 0.190 |
Why?
|
| Skin Neoplasms | 1 | 2004 | 513 | 0.190 |
Why?
|
| Clinical Trials as Topic | 4 | 2014 | 1153 | 0.180 |
Why?
|
| Cadherins | 1 | 2000 | 147 | 0.180 |
Why?
|
| Radiosurgery | 2 | 2013 | 262 | 0.180 |
Why?
|
| Middle Aged | 16 | 2018 | 24127 | 0.180 |
Why?
|
| Mammography | 2 | 2000 | 456 | 0.180 |
Why?
|
| Radiotherapy, Adjuvant | 4 | 2005 | 286 | 0.170 |
Why?
|
| Gene Amplification | 1 | 2018 | 128 | 0.170 |
Why?
|
| History, 21st Century | 2 | 2009 | 169 | 0.160 |
Why?
|
| Immediate-Early Proteins | 4 | 2004 | 168 | 0.150 |
Why?
|
| Mastectomy | 2 | 2004 | 225 | 0.150 |
Why?
|
| Quality of Health Care | 1 | 2000 | 366 | 0.150 |
Why?
|
| Antigens, Neoplasm | 1 | 1998 | 317 | 0.150 |
Why?
|
| Prescription Fees | 1 | 2015 | 11 | 0.140 |
Why?
|
| Consumer Advocacy | 1 | 1995 | 10 | 0.140 |
Why?
|
| Insurance Coverage | 1 | 1996 | 106 | 0.140 |
Why?
|
| Disease Models, Animal | 4 | 2016 | 2187 | 0.140 |
Why?
|
| United States | 7 | 2015 | 6191 | 0.140 |
Why?
|
| Health Care Rationing | 1 | 1996 | 77 | 0.140 |
Why?
|
| Microcirculation | 3 | 2000 | 102 | 0.140 |
Why?
|
| Aged, 80 and over | 7 | 2018 | 6244 | 0.140 |
Why?
|
| Chromosomes, Human, Pair 14 | 1 | 2015 | 49 | 0.140 |
Why?
|
| Drug Costs | 1 | 2015 | 63 | 0.140 |
Why?
|
| Erectile Dysfunction | 2 | 2007 | 97 | 0.130 |
Why?
|
| Neoplasm Staging | 5 | 2004 | 1888 | 0.130 |
Why?
|
| Patients | 1 | 1995 | 90 | 0.130 |
Why?
|
| Medical Laboratory Science | 1 | 1994 | 7 | 0.130 |
Why?
|
| Urinary Incontinence | 2 | 2007 | 121 | 0.130 |
Why?
|
| Radiotherapy, Computer-Assisted | 2 | 2008 | 25 | 0.130 |
Why?
|
| Clinical Medicine | 1 | 1994 | 34 | 0.130 |
Why?
|
| Aging | 1 | 1998 | 629 | 0.130 |
Why?
|
| Life Expectancy | 1 | 1994 | 84 | 0.130 |
Why?
|
| Genetic Engineering | 1 | 1994 | 108 | 0.120 |
Why?
|
| Patient Participation | 1 | 2015 | 197 | 0.120 |
Why?
|
| Adult | 12 | 2018 | 24771 | 0.120 |
Why?
|
| Male | 13 | 2018 | 39770 | 0.120 |
Why?
|
| History, 19th Century | 2 | 2009 | 58 | 0.120 |
Why?
|
| Health Care Reform | 1 | 1994 | 90 | 0.120 |
Why?
|
| Treatment Outcome | 6 | 2013 | 7589 | 0.110 |
Why?
|
| Data Interpretation, Statistical | 2 | 2004 | 297 | 0.110 |
Why?
|
| Evidence-Based Medicine | 2 | 2005 | 430 | 0.100 |
Why?
|
| Diagnostic Imaging | 1 | 2015 | 451 | 0.100 |
Why?
|
| Informed Consent | 2 | 2010 | 247 | 0.100 |
Why?
|
| Neoplasm Transplantation | 6 | 2016 | 388 | 0.100 |
Why?
|
| Animals | 15 | 2016 | 25878 | 0.100 |
Why?
|
| Age Factors | 3 | 2007 | 1803 | 0.100 |
Why?
|
| Philosophy, Medical | 2 | 2005 | 17 | 0.100 |
Why?
|
| Ohio | 1 | 2010 | 36 | 0.100 |
Why?
|
| Multivariate Analysis | 3 | 1998 | 968 | 0.100 |
Why?
|
| Follow-Up Studies | 4 | 2000 | 3586 | 0.100 |
Why?
|
| Tamoxifen | 2 | 2004 | 163 | 0.100 |
Why?
|
| Hodgkin Disease | 1 | 1991 | 167 | 0.100 |
Why?
|
| NM23 Nucleoside Diphosphate Kinases | 2 | 2000 | 5 | 0.100 |
Why?
|
| Biological Evolution | 1 | 1997 | 877 | 0.090 |
Why?
|
| Lung | 2 | 2012 | 1104 | 0.090 |
Why?
|
| Research Subjects | 1 | 2010 | 72 | 0.090 |
Why?
|
| X-Ray Therapy | 1 | 2008 | 6 | 0.090 |
Why?
|
| Lung Neoplasms | 3 | 2013 | 2160 | 0.090 |
Why?
|
| Universities | 1 | 2010 | 136 | 0.090 |
Why?
|
| Cell Line, Tumor | 5 | 2015 | 2330 | 0.090 |
Why?
|
| Military Personnel | 1 | 2010 | 73 | 0.090 |
Why?
|
| Analysis of Variance | 2 | 2004 | 900 | 0.090 |
Why?
|
| Adenocarcinoma | 3 | 2012 | 1130 | 0.090 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2008 | 95 | 0.090 |
Why?
|
| Survival Rate | 3 | 2012 | 1820 | 0.090 |
Why?
|
| Philosophy | 1 | 2007 | 9 | 0.080 |
Why?
|
| Melanoma, Experimental | 1 | 2008 | 102 | 0.080 |
Why?
|
| Radiotherapy, Conformal | 1 | 2008 | 87 | 0.080 |
Why?
|
| Urethral Stricture | 1 | 2007 | 15 | 0.080 |
Why?
|
| Rectal Diseases | 1 | 2007 | 27 | 0.080 |
Why?
|
| Critical Pathways | 1 | 2007 | 32 | 0.080 |
Why?
|
| Practice Patterns, Physicians' | 1 | 1993 | 557 | 0.080 |
Why?
|
| DNA-Binding Proteins | 4 | 2004 | 1189 | 0.080 |
Why?
|
| Mutation | 1 | 2018 | 3791 | 0.080 |
Why?
|
| Actuarial Analysis | 2 | 1997 | 66 | 0.080 |
Why?
|
| Phenotype | 3 | 2015 | 2292 | 0.080 |
Why?
|
| Fund Raising | 1 | 2005 | 2 | 0.080 |
Why?
|
| Academies and Institutes | 1 | 2006 | 28 | 0.070 |
Why?
|
| Time Factors | 4 | 2005 | 5161 | 0.070 |
Why?
|
| Dermatology | 1 | 2006 | 32 | 0.070 |
Why?
|
| Predictive Value of Tests | 3 | 2003 | 1625 | 0.070 |
Why?
|
| Gene Expression Regulation | 3 | 2002 | 1891 | 0.070 |
Why?
|
| Trastuzumab | 1 | 2005 | 59 | 0.070 |
Why?
|
| Immunohistochemistry | 3 | 2000 | 1725 | 0.070 |
Why?
|
| Gene Expression Profiling | 3 | 2018 | 1327 | 0.070 |
Why?
|
| Heterografts | 2 | 2015 | 90 | 0.070 |
Why?
|
| Mastectomy, Radical | 2 | 1995 | 10 | 0.070 |
Why?
|
| Sample Size | 1 | 2005 | 128 | 0.070 |
Why?
|
| Patient Satisfaction | 1 | 2007 | 426 | 0.070 |
Why?
|
| Drug Administration Schedule | 2 | 2003 | 932 | 0.060 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2004 | 108 | 0.060 |
Why?
|
| Databases, Factual | 1 | 2007 | 761 | 0.060 |
Why?
|
| Doxorubicin | 1 | 2004 | 279 | 0.060 |
Why?
|
| Radiation Dosage | 2 | 2011 | 223 | 0.060 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2004 | 2332 | 0.060 |
Why?
|
| Carcinoma, Lewis Lung | 2 | 2000 | 22 | 0.060 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2005 | 405 | 0.060 |
Why?
|
| Neoplasm Invasiveness | 1 | 2004 | 517 | 0.060 |
Why?
|
| Mice | 9 | 2015 | 10870 | 0.060 |
Why?
|
| Surgical Procedures, Operative | 1 | 2004 | 168 | 0.060 |
Why?
|
| Interdisciplinary Communication | 1 | 2003 | 124 | 0.060 |
Why?
|
| Early Growth Response Protein 1 | 4 | 2004 | 56 | 0.060 |
Why?
|
| Lymphedema | 1 | 2003 | 74 | 0.050 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2018 | 849 | 0.050 |
Why?
|
| Transcriptional Activation | 1 | 2002 | 277 | 0.050 |
Why?
|
| Sensitivity and Specificity | 2 | 2003 | 1947 | 0.050 |
Why?
|
| Coumarins | 1 | 2000 | 13 | 0.050 |
Why?
|
| Dose-Response Relationship, Radiation | 2 | 2000 | 190 | 0.050 |
Why?
|
| Risk | 1 | 2003 | 673 | 0.050 |
Why?
|
| Immunity, Cellular | 1 | 2001 | 173 | 0.050 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2003 | 682 | 0.050 |
Why?
|
| Risk Assessment | 2 | 2005 | 2180 | 0.050 |
Why?
|
| Tumor Cells, Cultured | 5 | 2002 | 1039 | 0.050 |
Why?
|
| Cisplatin | 1 | 2002 | 590 | 0.050 |
Why?
|
| Gene Expression | 2 | 2015 | 1285 | 0.050 |
Why?
|
| Databases as Topic | 1 | 2000 | 90 | 0.050 |
Why?
|
| Mice, Nude | 5 | 2002 | 764 | 0.050 |
Why?
|
| Cancer Vaccines | 1 | 2001 | 153 | 0.050 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2005 | 901 | 0.050 |
Why?
|
| Carcinoma, Lobular | 1 | 2000 | 78 | 0.050 |
Why?
|
| Plasminogen | 1 | 1998 | 41 | 0.050 |
Why?
|
| Class II Phosphatidylinositol 3-Kinases | 1 | 2018 | 8 | 0.040 |
Why?
|
| Genetic Vectors | 4 | 2004 | 429 | 0.040 |
Why?
|
| Antibodies, Monoclonal | 1 | 2005 | 1377 | 0.040 |
Why?
|
| Apoptosis | 3 | 2008 | 1655 | 0.040 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2000 | 154 | 0.040 |
Why?
|
| Research | 2 | 2003 | 252 | 0.040 |
Why?
|
| Receptor, Notch1 | 1 | 2018 | 82 | 0.040 |
Why?
|
| Transcription, Genetic | 1 | 2002 | 1120 | 0.040 |
Why?
|
| Paraffin Embedding | 1 | 1997 | 77 | 0.040 |
Why?
|
| Severity of Illness Index | 1 | 2003 | 1698 | 0.040 |
Why?
|
| Adrenalectomy | 1 | 1996 | 41 | 0.040 |
Why?
|
| Mutagenesis | 1 | 1997 | 201 | 0.040 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2011 | 442 | 0.040 |
Why?
|
| Axilla | 1 | 1997 | 92 | 0.040 |
Why?
|
| Ovariectomy | 1 | 1996 | 74 | 0.040 |
Why?
|
| Insurance, Health | 1 | 1998 | 147 | 0.040 |
Why?
|
| Peptide Fragments | 1 | 1998 | 457 | 0.040 |
Why?
|
| HCT116 Cells | 1 | 2016 | 148 | 0.040 |
Why?
|
| Neoplasm Proteins | 1 | 2000 | 531 | 0.040 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2018 | 374 | 0.040 |
Why?
|
| Researcher-Subject Relations | 1 | 1996 | 4 | 0.040 |
Why?
|
| Molecular Biology | 1 | 1996 | 87 | 0.040 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2004 | 1020 | 0.040 |
Why?
|
| Immunotherapy | 1 | 2001 | 565 | 0.040 |
Why?
|
| Social Responsibility | 1 | 1996 | 54 | 0.040 |
Why?
|
| Fibrosarcoma | 1 | 1995 | 86 | 0.040 |
Why?
|
| Luminescent Measurements | 1 | 2015 | 57 | 0.040 |
Why?
|
| DNA Repair | 1 | 1997 | 347 | 0.030 |
Why?
|
| Cell Nucleus | 1 | 1997 | 572 | 0.030 |
Why?
|
| Laryngeal Neoplasms | 1 | 1995 | 88 | 0.030 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 1996 | 191 | 0.030 |
Why?
|
| Mice, Inbred NOD | 1 | 2015 | 182 | 0.030 |
Why?
|
| Mice, SCID | 1 | 2015 | 233 | 0.030 |
Why?
|
| Algorithms | 1 | 2003 | 1787 | 0.030 |
Why?
|
| Likelihood Functions | 1 | 1995 | 253 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 1996 | 830 | 0.030 |
Why?
|
| Research Design | 2 | 2003 | 570 | 0.030 |
Why?
|
| Tumor Burden | 1 | 2015 | 275 | 0.030 |
Why?
|
| Neoplasms, Experimental | 1 | 1995 | 270 | 0.030 |
Why?
|
| Socioeconomic Factors | 1 | 1996 | 537 | 0.030 |
Why?
|
| Social Values | 1 | 1994 | 42 | 0.030 |
Why?
|
| Regression Analysis | 1 | 1995 | 592 | 0.030 |
Why?
|
| Diffusion of Innovation | 1 | 1994 | 71 | 0.030 |
Why?
|
| Genetic Diseases, Inborn | 1 | 1994 | 97 | 0.030 |
Why?
|
| Receptors, Estrogen | 1 | 1995 | 376 | 0.030 |
Why?
|
| Health Care Costs | 1 | 1995 | 229 | 0.030 |
Why?
|
| Patient-Centered Care | 1 | 1995 | 191 | 0.030 |
Why?
|
| Forecasting | 1 | 1994 | 308 | 0.030 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2016 | 556 | 0.030 |
Why?
|
| Molecular Targeted Therapy | 1 | 2014 | 259 | 0.030 |
Why?
|
| Adenoviridae | 2 | 2004 | 345 | 0.030 |
Why?
|
| Social Change | 1 | 1991 | 7 | 0.030 |
Why?
|
| England | 1 | 1991 | 42 | 0.030 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 1991 | 71 | 0.030 |
Why?
|
| Maximum Tolerated Dose | 1 | 2011 | 269 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 2011 | 354 | 0.030 |
Why?
|
| Costs and Cost Analysis | 1 | 1991 | 146 | 0.030 |
Why?
|
| Precision Medicine | 1 | 2014 | 362 | 0.020 |
Why?
|
| Databases, Genetic | 1 | 2011 | 253 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 2 | 2004 | 918 | 0.020 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 1996 | 1046 | 0.020 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type II | 1 | 2008 | 20 | 0.020 |
Why?
|
| Esophageal Neoplasms | 2 | 2002 | 304 | 0.020 |
Why?
|
| Etanercept | 1 | 2008 | 31 | 0.020 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type I | 1 | 2008 | 44 | 0.020 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2008 | 84 | 0.020 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 1993 | 493 | 0.020 |
Why?
|
| Delivery of Health Care | 1 | 1991 | 348 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2000 | 7600 | 0.020 |
Why?
|
| Rats | 2 | 2004 | 3944 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 1991 | 1809 | 0.020 |
Why?
|
| Immunoglobulin G | 1 | 2008 | 449 | 0.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2011 | 1168 | 0.020 |
Why?
|
| Endothelial Cells | 1 | 2008 | 396 | 0.020 |
Why?
|
| Necrosis | 2 | 1996 | 192 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2011 | 2595 | 0.020 |
Why?
|
| Pleural Effusion | 1 | 2004 | 44 | 0.020 |
Why?
|
| Organoplatinum Compounds | 1 | 2004 | 95 | 0.020 |
Why?
|
| Acetylcysteine | 1 | 2004 | 69 | 0.020 |
Why?
|
| Recombinant Fusion Proteins | 2 | 1996 | 555 | 0.020 |
Why?
|
| Biopsy, Needle | 1 | 2004 | 234 | 0.020 |
Why?
|
| Genes, erbB-2 | 1 | 2003 | 24 | 0.020 |
Why?
|
| Probability | 1 | 2004 | 345 | 0.020 |
Why?
|
| Selective Estrogen Receptor Modulators | 1 | 2003 | 32 | 0.020 |
Why?
|
| Receptors, Steroid | 1 | 2003 | 43 | 0.010 |
Why?
|
| Immunosuppressive Agents | 1 | 2008 | 986 | 0.010 |
Why?
|
| Paclitaxel | 1 | 2004 | 453 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 2 | 2000 | 3072 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 2002 | 392 | 0.010 |
Why?
|
| Phytotherapy | 1 | 2003 | 131 | 0.010 |
Why?
|
| Up-Regulation | 1 | 2004 | 693 | 0.010 |
Why?
|
| Isocoumarins | 1 | 2000 | 7 | 0.010 |
Why?
|
| Umbilical Veins | 1 | 2000 | 45 | 0.010 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2004 | 562 | 0.010 |
Why?
|
| Laminin | 1 | 2000 | 81 | 0.010 |
Why?
|
| ROC Curve | 1 | 2003 | 734 | 0.010 |
Why?
|
| Drug Combinations | 1 | 2000 | 226 | 0.010 |
Why?
|
| Proteoglycans | 1 | 2000 | 118 | 0.010 |
Why?
|
| Mass Screening | 1 | 2004 | 597 | 0.010 |
Why?
|
| Angiostatins | 1 | 1998 | 16 | 0.010 |
Why?
|
| Collagen | 1 | 2000 | 265 | 0.010 |
Why?
|
| Cytokines | 1 | 2003 | 755 | 0.010 |
Why?
|
| Endothelium, Vascular | 1 | 2000 | 428 | 0.010 |
Why?
|
| Colonic Neoplasms | 1 | 2002 | 540 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2004 | 2600 | 0.010 |
Why?
|
| Cell Movement | 1 | 2000 | 740 | 0.010 |
Why?
|
| Biomarkers | 1 | 2003 | 1617 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2000 | 1973 | 0.010 |
Why?
|
| Mastadenovirus | 1 | 1995 | 4 | 0.010 |
Why?
|
| Liposomes | 1 | 1995 | 95 | 0.010 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 1995 | 108 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2000 | 2798 | 0.010 |
Why?
|
| Radiation Tolerance | 1 | 1995 | 167 | 0.010 |
Why?
|
| Transplantation, Heterologous | 1 | 1995 | 354 | 0.010 |
Why?
|
| Thrombosis | 1 | 1996 | 273 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2003 | 3167 | 0.010 |
Why?
|